ADHD in international adoptees: a national cohort study by Lindblad, Frank et al.
www.ssoar.info
ADHD in international adoptees: a national cohort
study
Lindblad, Frank; Ringbäck Weitoft, Gunilla; Hjern, Anders
Postprint / Postprint
Zeitschriftenartikel / journal article
Zur Verfügung gestellt in Kooperation mit / provided in cooperation with:
www.peerproject.eu
Empfohlene Zitierung / Suggested Citation:
Lindblad, F., Ringbäck Weitoft, G., & Hjern, A. (2009). ADHD in international adoptees: a national cohort study.
European Child & Adolescent Psychiatry, 19(1), 37-44. https://doi.org/10.1007/s00787-009-0038-3
Nutzungsbedingungen:
Dieser Text wird unter dem "PEER Licence Agreement zur
Verfügung" gestellt. Nähere Auskünfte zum PEER-Projekt finden
Sie hier: http://www.peerproject.eu Gewährt wird ein nicht
exklusives, nicht übertragbares, persönliches und beschränktes
Recht auf Nutzung dieses Dokuments. Dieses Dokument
ist ausschließlich für den persönlichen, nicht-kommerziellen
Gebrauch bestimmt. Auf sämtlichen Kopien dieses Dokuments
müssen alle Urheberrechtshinweise und sonstigen Hinweise
auf gesetzlichen Schutz beibehalten werden. Sie dürfen dieses
Dokument nicht in irgendeiner Weise abändern, noch dürfen
Sie dieses Dokument für öffentliche oder kommerzielle Zwecke
vervielfältigen, öffentlich ausstellen, aufführen, vertreiben oder
anderweitig nutzen.
Mit der Verwendung dieses Dokuments erkennen Sie die
Nutzungsbedingungen an.
Terms of use:
This document is made available under the "PEER Licence
Agreement ". For more Information regarding the PEER-project
see: http://www.peerproject.eu This document is solely intended
for your personal, non-commercial use.All of the copies of
this documents must retain all copyright information and other
information regarding legal protection. You are not allowed to alter
this document in any way, to copy it for public or commercial
purposes, to exhibit the document in public, to perform, distribute
or otherwise use the document in public.
By using this particular document, you accept the above-stated
conditions of use.
Diese Version ist zitierbar unter / This version is citable under:
https://nbn-resolving.org/urn:nbn:de:0168-ssoar-202883
ORIGINAL CONTRIBUTION
ADHD in international adoptees: a national cohort study
Frank Lindblad Æ Gunilla Ringba¨ck Weitoft Æ
Anders Hjern
Received: 31 October 2008 / Accepted: 26 May 2009 / Published online: 19 June 2009
 Springer-Verlag 2009
Abstract Several investigators have reported an
increased frequency of attention/hyperactivity symptoms in
international adoptees, though population-based studies are
lacking. In this national cohort study, we aimed to deter-
mine the prevalence of ADHD medication in international
adoptees in Sweden, in comparison to the general popu-
lation. A further purpose was to study gender, age at
adoption and region of origin as predictors of ADHD
medication in international adoptees. The study population
consisted of all Swedish residents born in 1985–2000 with
Swedish-born parents, divided into 16,134 adoptees, and a
comparison population of 1,326,090. ADHD medications
were identified in the Swedish Prescribed Drug Register
during 2006. Logistic regression was used to calculate the
odds ratios. The rates of ADHD medication were higher in
international adoptees than in the comparison population
for both boys (5.3 vs. 1.5% for 10–15-year olds) and girls
(2.1 vs. 0.3% for 10–15-year olds). International adoptees
from all regions of birth more often consumed ADHD
medication compared with the majority population, but the
age and sex adjusted odds ratios were particularly high for
adoptees from Eastern Europe, Middle East/Africa and
Latin America. Adjusting for maternal education and single
parenthood increased the odds ratios even further. The risk
also increased with higher age at adoption. Adoptees from
Eastern Europe have a very high risk for ADHD medica-
tion. A structured identification and support programme
should be tailored for this group. Adoptees from other
regions have a more moderately increased risk, which
should be communicated to adoptive parents and to pro-
fessionals who care for adoptees in their clinical practice.
Keywords International adoption  ADHD 
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Introduction
The health development of international adoptees has been
the focus of many scientific reports. In the largest
(n = 2,148) study on international adoptees (10–15 years
of age) from the last century, Verhulst et al. [1] found a
higher frequency of adopted children with psychiatric
problems (measured through the parental version of Child
Behavior Check List) compared to Dutch non-adopted
children of the same age. A follow-up study (n = 1.484),
using a standardised psychiatric interview procedure, also
found higher risk of severe mental health problems [2]. In a
series of register studies, using whole national cohorts of
10–15,000 individuals, investigators have reported three- to
fourfold greater risks of outcomes related to psychiatric
hospitalisations, including suicidal behaviour. Mortality
and severe social problems were also observed with similar
magnitude of increased risks among international adoptees
[3–7].
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Researchers have long observed the symptoms and
syndromes related to hyperactivity, in recent years reported
as ADHD, amongst international adoptees. ADHD (atten-
tion-deficit hyperactivity disorder) is a neurobehavioural
developmental disorder characterised by inattention,
impulsiveness and hyperactivity, in different combinations.
It is typically a childhood disorder, but a majority
(60–85%) of children will continue to meet the diagnostic
criteria during their teens and several will have remaining
problems also as adults [8]. There is considerable evidence
that genetic factors are important in the aetiology of
ADHD, although the specific genes involved have yet to be
identified [9]. Environmental factors may also be influen-
tial [10]. Case–control studies have demonstrated an
association between psychosocial adversity and ADHD in
school children [11, 12]. Foetal alcohol exposure was
suggested as one cause of ADHD in the beginning of the
1990s [13]. Bhatara et al. [14] found a 41% prevalence of
ADHD in a sample of 2,231 youths referred for foetal
alcohol spectrum disorders.
Verhulst et al. [1] found higher scores for 12- to
15-year-old boys on the delinquent, hyperactive and
externalising scales. The English and Romanian Adoptees
(ERA) Study Team reported increased risks of attention/
hyperactivity symptoms in Romanian adoptees with a
background of institutionalisation [15]. The authors con-
clude that these types of symptoms may constitute an
‘‘institutional deprivation syndrome’’, but also suggest that
these children may present with a different clinical picture
than ordinary ADHD types. The ERA team has proposed
that institutional deprivation results in early biological
programming or neural damage, but has also stated that
these effects may be modified by a favourable post-adop-
tion environment [16].
Several studies involving a majority of national adoptees
have previously demonstrated greater risks for ADHD. For
instance, Simmel et al. [17] performed a parental question-
naire study with a state-wide non-clinical adoptee popula-
tion, aged 4–18 years, with international adoptees
constituting 5% of the sample. Originally, parents repre-
senting 2,589 placements had been invited. After attrition in
several steps and exclusions due to specified criteria, 808
adoptees remained. Of these, 21.8% met the symptom cri-
teria for ADHD. Other reports on risk factors for ADHD
amongst adoptees are inconclusive. In the study from the
USA by Simmel et al. [17], referring to the above, male
gender and later age of adoption were associated with a
higher risk. In a comparable sample of 178 British adoptees
(probably a vast majority of national adoptees), risks of
ADHD were as high for girls as for boys, and age at adoption
was not related to the type of psychopathology [18].
Adoptees from Eastern Europe have constituted a large
proportion of all intercountry adoptees during the last
decade. For instance, in the USA, adoptees from the
nations of the former Soviet Union are the second largest
group after China [19]. Also in Sweden, historically
probably the second largest receiver country after the USA,
adoptees from Eastern Europe have increased during the
1990s. Since the middle of the 1990s, European origin has
been more common than origin from Latin America
http://www.mia.eu/statistik/varlds.pdf. In a Swedish study
on Eastern European adoptees from the middle of the
1990s, the authors describe in detail the neuropsychiatric
challenges [20]. For instance, 78% had abnormal ocular
findings with visuoperceptual problems in 37, compared to
1% in a non-adopted comparison group [21]. At least
one-third had been exposed to alcohol prenatally. The
frequency of ADHD (identified retrospectively through
analyses of records from child health care, school health
care and outpatient paediatric care) was three times as high
as in a Swedish norm group [20].
Dalen and Rygvold reported that hyperactive behaviour
was not more common in a study group of 77 adoptees
from China than amongst non-adopted children [22]. Even
if hyperactivity is not synonymous with ADHD, the find-
ings illustrate that international adoptees are a heteroge-
nous group and mental health outcomes may vary strongly
between and within continents [23]. The prognosis is to a
high degree determined by the motives for adoption and
quality of care in the countries of origin [23]. Along the
same line, studies on outcomes may differ between national
and international adoptees [24].
The management of ADHD involves a broad variety of
measures, such as pharmacological intervention, behav-
ioural therapy, parental and child psychoeducation, linkage
with community supports and specific school interventions
[8]. National guidelines for medication of ADHD issued by
the Swedish National Board of Health and Welfare state
that medication should be reserved for cases where other
supportive interventions have failed. Psychostimulants,
originally amphetamine but with metylphenidate as the
dominating choice today, are usually regarded as the
pharmaceutical of choice [25]. Their effects are mediated
by an increase of intrasynaptic dopamine, norepinephrine
and serotonin [25]. One side effect of psychostimulant
medication is a modest reduction in the expected height
and weight [26]. This may be of particular importance for
international adoptees, especially amongst girls, who have
an increased risk of early puberty and short final height
[27]. Atomoxetine, a more recently available medication
used in the management of ADHD, is designated as a
nonpsychostimulant. It inhibits the transport of norepi-
nephrine [28]. The reported efficacy of amoxetine in
treatment evaluation studies has been lower than that of
psychostimulants. On the other hand, the risk for amoxe-
tine abuse, a risk associated with psychostimulants, has
38 Eur Child Adolesc Psychiatry (2010) 19:37–44
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been regarded as low [25]). A disadvantage is the increased
potential for suicidal ideation [29]. A recent review con-
cludes that atomoxetine may be of value, especially in the
presence of comorbid disorders and when treatment with
stimulant medication has failed [28].
Some limitations re-occur in many reports on ADHD in
adoptees. First, many studies are conducted with clinical
samples and do not allow for conclusions about the wider
population. Second, many studies have relied on parental
reports. Third, attrition problems amongst study subjects
are typical.
Swedish national registers offer a potential for over-
coming these methodological challenges. Whole age
cohorts can be identified and, since July 2005, individual
prescriptions of drugs have been registered. This makes it
possible to study patient groups who are usually not
admitted to in-patient care, but who can be identified
through purchase of specific prescribed drugs or groups of
drugs. ADHD is such a group, characterised by manage-
ment based on a few drugs, used exclusively for this
indication.
Thus, this study was aimed at determining the preva-
lence of ADHD medication in international adoptees in
Sweden, in comparison to the general population. A further
aim was to determine the prevalence of ADHD medication
in relation to gender, age at adoption and country of origin.
Methods
This study was based on Swedish national registers held by
the National Board of Health and Welfare and Statistics
Sweden. All Swedish residents are assigned a unique ten-
digit identification (ID) number at birth or on immigration.
This ID was used to link information from different register
sources. The study was approved by the regional ethics
committee in Stockholm.
Study population
All individuals born between 1985 and 2000, who were
alive and registered as residents in Sweden on 31
December 2005, were identified in the register of the total
population (RTP). Biological and/or adoptive parents of
these individuals were identified in the Multi-Generation
Register.
Information on region of birth, date of immigration, sex
and year of birth in RTP was linked to the study subjects
and their parents. Based on this information, we created
two study groups: international adoptees (N = 16,134),
who fulfilled the criteria of being born outside of western
Europe, having at least one Swedish-born adoptive parent,
but no biological parent in the multi-generation register,
and having entered Sweden before their eighth birthday;
and the majority population (N = 1,326,090), which con-
sisted of all Swedish-born individuals with at least one
Swedish-born biological parent and no adoptive parents in
the multi-generation register [30].
Several psychiatric outcomes vary with geographic
origin (see above) and age at adoption (3). Any effects of
these factors were studied separately. The international
adoptees were divided based on the region of birth: Far
East, South Asia, Latin America, Eastern Europe and
Middle East/Africa (see Table 1). Age at adoption was
calculated from the year of birth and year of immigration to
Sweden. (Adoption in this sense means the time when a
child starts living with the new parents and not the date
when the formal adoption procedure is completed). As
much as 70% of the adoptees were adopted before 2 years
of age.
Socio-economic variables
As described in ‘‘Introduction’’, psychosocial factors may
influence the development of ADHD. Since families of
Swedish international adoptees tend to have higher socio-
economic status than families of non-adoptees (3,4), it is
important to adjust for such variables when estimating
Table 1 ADHD medication, based on adoption status, county cate-
gory and socio-economic indicators (maternal education and single
parenthood), ages 6–21 years
Boys Boys Girls Girls
Total N ADHD % Total N ADHD %
Adoption/not
Adoptees 7,777 3.83 8,357 1.44
Non-adoptees 680,949 0.96 645,141 0.27
County category
County Cat 1 74,417 1.54 70,626 0.48
County Cat 2 332,461 1.04 315,267 0.32
County Cat 3 173,563 0.91 165,341 0.23
County Cat 4 108,285 0.54 102,264 0.16
Maternal education
B9 years 61,007 1.70 58,083 0.48
10–12 236,649 1.19 224,376 0.32
13–14 158,182 0.88 150,041 0.27
15? 227,450 0.65 215,987 0.20
Missing 5,438 1.58 5,011 0.44
Single parenthood
Yes 169,462 1.54 163,481 0.45
No 519,264 0.82 490,017 0.23
Total 688,726 0.99 653,498 0.29
The counties were classified into four categories, based on the pro-
portion of children who had ADHD medication prescriptions during
2006
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mental health risks. In this study, we chose education of the
adoptive mother (the biological mother in the majority
population) and lone parenthood as indicators of socio-
economic living conditions. Information on the educational
level of the mother, adoptive or biological, in 2005 was
obtained through linkage to the Swedish National Educa-
tion Register. The Swedish National Education Register
was established by Statistics Sweden in 1985 and is
annually updated with information on the highest formal
education attained by each individual, from elementary to
postgraduate level. Educational attainment was classified
into four categories: having 9 years or less of schooling,
representing primary school only; 10–12 years, equivalent
to secondary school; 13–14 years i.e. short post-secondary
education; and 15?, representing a university education.
Single parenthood of the household of the study subject
was obtained through linkage to the Total Enumeration
Income Survey of 2003 (when all study subjects were
minors).
Drug variables
The Swedish Prescribed Drug Register contains data, with
unique patient identifiers for all drugs prescribed and dis-
pensed to the whole population of Sweden (more than
9 million inhabitants) since July 2005 [31]. The purchase
of at least one prescription of a drug with an Anatomical
Therapeutic Chemical (ATC)-code of NO6BA01–
NO6BA04 or NO6BA09 during the calendar year 2006,
according to this register, was used to create the outcome
variable of the study, consumption of ADHD medication
(in the text also abbreviated as ‘‘medication’’).
There were considerable regional differences in the use
of ADHD medication (see Table 1). Since these differ-
ences did not follow any obvious demographical or geo-
graphical patterns, we assumed that this pattern mirrored
varying prescription routines in different counties, rather
than variations in the prevalence of ADHD. A four-cate-
gory variable, county category, with different levels of
consumption was created to adjust the analysis to these
regional differences. The counties were classified into four
categories, according to the proportion of children who
purchased ADHD prescription medications during 2006.
Statistical analysis
We used logistic regression to calculate odds ratios (OR)
with 95% confidence intervals (CIs), for boys and girls
separately, and with use of ADHD medication, defined
above, as the outcome variable. In model 1, we adjusted
the analysis to three variables and considered confounders
(age as a three-category variable (6–9 years, 10–15 years,
16–21 years), sex and county category).
For the boys, where the greater numbers of cases
allowed this, we added maternal education and single-
parent household as possible mediators/protective factors
of adoption status in Model 2. Gender differences, in the
effects of region of birth and age at adoption, on ADHD
medication in adoptees were investigated in interaction
analyses in models adjusted for age and county only. All
statistical analyses were performed using SPSS version
15.0 for Windows.
Results
The most commonly purchased drug was methylphenidate
(88.6%), followed by atomoxetine (9.2%) and amphet-
amine (2.2%) with very similar patterns in adoptees
compared with the non-adopted. The rates of medication
were higher in international adoptees than in the majority
population for both boys (3.83 vs 0.96%) and girls (1.44
vs 0.27%) (Table 1). These differences (adoptees vs.
majority population and boys vs. girls) were present for
all age groups (Fig. 1a, b). For boys, there was a peak at
16 years of age, where 8% of the adoptees compared with
1% in the majority population, had been prescribed an
ADHD medication (Fig. 1a). The patterns were similar
for adopted girls, but at a lower level, with a peak at
17 years of age and with a 3% rate of ADHD medication
usage compared with 0.4% for the majority population
(Fig. 1b).
As demonstrated in Table 2, the highest rates of ADHD
medication were found in adopted boys, 10–15 years of
age, which originated from Eastern Europe (12.6%) and the
Middle East/Africa (6.7%). Adopted girls from Eastern
Europe, 10–15 years of age, also had a high rate (6.2%).
Internationally adopted boys from all regions of birth
more often had ADHD medication compared to the
majority population, but the ORs were particularly high for
adoptees from Eastern Europe (OR 10.4 [8.7–12.4]),
Middle East/Africa (OR 4.8 [2.6–8.7]) and Latin America
(OR 3.6 [(2.8–4.5]) in the first model, adjusted for age and
county of residency only (Table 3). Adding possible
mediators/protective factors in Model 2 raised the ORs
even more. Adopted girls had higher ORs compared to
boys from the same region, with the highest OR being in
girls from Eastern Europe (OR 15.4 [11.4–20.9]). In an
interaction analysis of sex and adoption status, with all
adoptees in one category, the P value for this difference in
effect on ADHD medication was 0.007.
In an analysis of age at adoption, in international
adoptees only, the ORs were higher for those adopted after
infancy (Table 4). These ORs were similar for boys and
girls with a P value of 0.60 for interaction effects of being
adopted as infant versus at an older age.
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Discussion
In this study, involving more than 16,000 international
adoptees in a national cohort of 1,3 million Swedish resi-
dents in the ages 6–21 years, we found higher rates of
ADHD medication in adopted boys (3.8%) and girls
(1.4%), compared with non-adoptees (1.0 and 0.3%,
respectively). The risks were twofold and higher for
adoptees, with those of Eastern European origin having the
highest risk, and with a 12-fold increased risk in boys after
adjustment for maternal education and single parenthood.
The risk increased with higher age at adoption. To the best
of our knowledge, this is the first study on ADHD medi-
cation in a population-based sample of international
adoptees.
Our study demonstrates a gender pattern amongst
adoptees similar to the general population, with greater
prevalence of ADHD medication in boys. However, the
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Fig. 1 a ADHD medication
(%) in male international
adoptees and majority
population peers of the same
age. b ADHD medication (%) in
female international adoptees
and majority population peers of
the same age
Table 2 Prevalence of ADHD medication based on sex, age and region of birth of the international adoptees
Boys Girls
N 6–9 years 10–15 years 16–21 years N 6–9 years 10–15 years 16–21 years
% % % % % %
Swedish majority 680,949 0.6 1.5 0.7 645,141 0.1 0.3 0.3
Middle East/Africa 372 2.0 6.7 2.0 366 1.8 2.3 1.7
Far East 2,208 1.3 1.4 1.9 3,025 0.4 0.6 0.5
South Asia 1,093 1.1 2.2 1.7 1,961 0.4 1.7 0.3
Latin America 2,438 0.7 4.0 3.4 1,749 0.5 1.7 2.6
Eastern Europe 1,666 5.8 12.6 7.8 1,256 2.5 6.2 2.3
All adoptees 7,777 2.6 5.3 3.3 8,357 0.8 2.1 1.3
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effect of being adopted on ADHD medication seemed to be
stronger in girls than in boys. These results are in line with
those found in another study on suicide attempts in the
Swedish youth, where adopted girls were found to have
greater increases in the relative risk than adopted boys [24].
We believe that these observations are due to environ-
mental influences. The age-pattern in the use of ADHD
medication was similar amongst adoptees and non-adop-
tees, probably reflecting common factors such as age-
dependent environmental demands and motivation aspects.
The increased risk of medication, observed in adoptees
from Eastern Europe, represents the highest odds ratio for
any negative health-related outcome found in a series of
studies on the development of international adoptees. In a
previous Swedish follow-up study of 76 adoptees from
Poland, the former Soviet Union and Romania (about one-
third from each region), maternal alcohol abuse was
explicitly mentioned in the documents from the country of
origin as the main reason for abandonment in more than
one-third of the cases [20]. This suggests that foetal
exposure to alcohol may have been an important factor in
the development of ADHD of the adoptees from Eastern
Europe in our study. It is reasonable to believe that genetic
factors as well as other environmental factors may have
contributed to the increased risk of ADHD medication too,
but we have no data to support such hypotheses. The other
odds ratios are of the same magnitude as in previously
reported psychiatric outcomes and display a more favour-
able prognosis for children from Asia compared to Latin
America [3, 4, 7]. The wide variation in outcomes amongst
adoptees from different regions highlights the need for
reporting the country of origin when presenting studies or
reviews on the development of international adoptees.
Age of adoption is commonly regarded as a proxy for
exposure to adversity during childhood [32]. Following this
line, our results on age at adoption suggest that environ-
mental factors to some degree have contributed to the
formation, or the severity, of the ADHD symptoms. The
lack of linearity (lower frequency in the oldest group than
in the middle group) is probably due to the heterogeneity of
the oldest group, also including children with sufficiently
good first few years of life, but with emerging severe
problems (like the death of a parent) later during
childhood.
The main strength of this study is the large study group
of adoptees representing whole national cohorts. The
identification of this group was made possible through the
utilisation of data from Swedish national registers, where
prescriptions of drugs dispensed since July 2005 could be
linked to these individuals. Universal and free access for all
children to medical and psychiatric care in the Swedish
health-care system also strengthens the conclusions of this
study.
The use of national registers with pre-collected data
provides certain limitations. For instance it is not possible
to interview the individuals or collect complementary data,
as all information in the national registers is unidentified; it
is not possible to bring out any information linked to a
certain individual.
The most important limitation of this study is probably
the interpretation of the outcome variable, ADHD medi-
cation. In Sweden, the authority to prescribe stimulant
medication in the management of ADHD is restricted to
specialists with particular familiarity with the treatment of
this disorder. Given this constraint, and in consideration of
the access to free psychiatric care and the national guide-
lines mentioned above, we believe that medication pre-
scription is a useful and fairly valid indicator of the more
severe cases of ADHD in Sweden. However, a number of
factors, apart from the severity of the disorder, are potential
determinants of the usage patterns of ADHD medication.
Factors within the health organisation are probably the
most important of these determinants, illustrated by the
differences among counties described in the ‘‘Methods’’
section. The existence of a few counties where medication
rates are higher, and a few lower than the average county,
suggests that other factors, apart from the severity of the
disorder, determine whether medication is prescribed. Such
Table 3 Logistic regression of adoption status, based on the region
of birth and ADHD medication
Boys Girls
Model 1 Model 2 Model 1
OR (95% CI) OR (95% CI) OR (95% CI)
Swedish
majority
1 1 1
Middle
East/Africa
4.8 (2.6–8.7) 5.3 (2.8–10.0) 9.6 (4.2–21.6)
Far East 1.6 (1.1–2.3) 1.9 (1.7–2.8) 2.1 (1.3–3.5)
South Asia 2.1 (1.3–3.4) 2.4 (1.5–5.0) 2.5 (1.4–4.3)
Latin America 3.6 (2.8–4.5) 4.6 (3.7–5.8) 7.7 (5.5–10.8)
Eastern Europe 10.4 (8.7–12.4) 12.5 (10.4–14.9) 15.4 (11.4–20.9)
Model 1 is adjusted for age and county category
Model 2 is adjusted for age, county category, maternal education and
single-parent household
Table 4 Age at adoption and ADHD medication
Age at adoption N OR (95% CI)
0 5,704 1
1 5,677 1.6 (1.2–2.2)
2–3 3,197 2.5 (1.8–3.4)
4–7 1,556 1.9 (1.4–2.8)
Model 1 is adjusted for age, sex, county category and region of birth
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factors could be associated with geographical differences
in the availability of services for children with ADHD, and
also with differences in the interpretation and implemen-
tation of the national guidelines in different local and
regional Swedish health organisations. The fact that risk
estimates were marginally affected by the inclusion of the
county variable into the multivariate analysis, however,
indicates that this variation was not an important source of
bias in relation to the socio-economic variables in the
study.
One may also speculate that child psychiatrists, con-
sciously or unconsciously, have different prescription pat-
terns for adoptees than for non-adoptees. Adoptive parents
have a higher level of education than that of the majority
population and also have higher than average financial
resources. This should mean better propensity for the
identification of ADHD and for seeking medical care.
Along the same line, adoptive parents may be more sensi-
tive to their children’s behavioural problems. Given such
circumstances, odds ratios of medication may be higher
than the actual increased risk for ADHD. It may also be
hypothesised that the greater social prerequisites amongst
adoptive parents convey a potential for seeking and utilising
psychological and educational support, thereby possibly
making medication unnecessary. If so, the odds ratios of
medication may underestimate the prevalence of ADHD.
To the best of our knowledge, there is no study on adoptive
parents’ capacity to tolerate ADHD symptoms in the child
and to adapt the environment to the needs of the child,
factors that may also influence the rate of medication.
Conclusion
This study suggests that adoptees from Eastern Europe
have a very high risk for ADHD medication. A structured
identification and support programme should be tailored
for this group. Adoptees from other regions have a more
moderately increased risk, which should be communicated
to adoptive parents and professionals who care for adoptees
in their clinical practice.
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